#Molnupiravir #Merck #RidgebackBiotherapeutics #RickBright #Tamiflu
Welcome to Kimavi Videos (Portrait Mode).
#Molnupiravir #Merck #RidgebackBiotherapeutics #RickBright #Tamiflu
What is Molnupiravir, by DRIVE at Emory, Merck and Ridgeback Biotherapeutics? Rick Bright and Tamiflu?
Molnupiravir is an experimental Covid-19 drug that could be Tamiflu for the Covid 19 pandemic
Only one antiviral has been authorized for use remdesivir from Gilead Sciences Inc., and it provides modest benefit in hospitalized patients
Let's learn more
What is Molnupiravir
Molnupiravir is an experimental antiviral drug which is orally active and was developed for the treatment of influenza
It is a prodrug of the synthetic nucleoside derivative N4-hydroxycytidine, and exerts its antiviral action through introduction of copying errors during viral RNA replication
Activity has also been demonstrated against coronaviruses including SARS, MERS and SARS-CoV-2.
The drug was developed at Emory University by the university's drug innovation company, Drug Innovation Ventures at Emory
It was then acquired by Miami-based company Ridgeback Biotherapeutics, who later partnered with Merck and Co. to develop the drug further
Safety controversy?
In April 2020, a whistleblower complaint by former Head of US Biomedical Advanced Research and Development Authority Rick Bright revealed concerns over providing funding for the further development of molnupiravir due to similar drugs having mutagenic or DNA damaging properties
These claims were denied by George Painter, CEO of DRIVE, noting that toxicity studies on molnupiravir had been carried out
Covid 19 Impact
On December 3rd, 2020, an article was published in the journal Nature on the results of a study on the treatment with molnupiravir of ferrets infected with Covid-19. The study found that the drug was "efficacious" when administered orally to infected ferrets, and that it blocked the transmission of the virus between ferrets after 24 hours following administration of the drug
Who is Rick Bright?
Rick Arthur Bright is an American immunologist, vaccine researcher, public health official, and whistleblower
He was the director of the Biomedical Advanced Research and Development Authority from 2016 to 2020
In May 2020, he filed a whistleblower complaint, alleging that the Trump administration ignored his early warnings about the COVID-19 pandemic and illegally retaliated against him by ousting him from his role and demoting him to a position at the National Institutes of Health
....
....
Thank you from Kimavi, Please visit us at Kimavi.Com for more portrait videos
Welcome to Kimavi Videos (Portrait Mode).
#Molnupiravir #Merck #RidgebackBiotherapeutics #RickBright #Tamiflu
What is Molnupiravir, by DRIVE at Emory, Merck and Ridgeback Biotherapeutics? Rick Bright and Tamiflu?
Molnupiravir is an experimental Covid-19 drug that could be Tamiflu for the Covid 19 pandemic
Only one antiviral has been authorized for use remdesivir from Gilead Sciences Inc., and it provides modest benefit in hospitalized patients
Let's learn more
What is Molnupiravir
Molnupiravir is an experimental antiviral drug which is orally active and was developed for the treatment of influenza
It is a prodrug of the synthetic nucleoside derivative N4-hydroxycytidine, and exerts its antiviral action through introduction of copying errors during viral RNA replication
Activity has also been demonstrated against coronaviruses including SARS, MERS and SARS-CoV-2.
The drug was developed at Emory University by the university's drug innovation company, Drug Innovation Ventures at Emory
It was then acquired by Miami-based company Ridgeback Biotherapeutics, who later partnered with Merck and Co. to develop the drug further
Safety controversy?
In April 2020, a whistleblower complaint by former Head of US Biomedical Advanced Research and Development Authority Rick Bright revealed concerns over providing funding for the further development of molnupiravir due to similar drugs having mutagenic or DNA damaging properties
These claims were denied by George Painter, CEO of DRIVE, noting that toxicity studies on molnupiravir had been carried out
Covid 19 Impact
On December 3rd, 2020, an article was published in the journal Nature on the results of a study on the treatment with molnupiravir of ferrets infected with Covid-19. The study found that the drug was "efficacious" when administered orally to infected ferrets, and that it blocked the transmission of the virus between ferrets after 24 hours following administration of the drug
Who is Rick Bright?
Rick Arthur Bright is an American immunologist, vaccine researcher, public health official, and whistleblower
He was the director of the Biomedical Advanced Research and Development Authority from 2016 to 2020
In May 2020, he filed a whistleblower complaint, alleging that the Trump administration ignored his early warnings about the COVID-19 pandemic and illegally retaliated against him by ousting him from his role and demoting him to a position at the National Institutes of Health
....
....
Thank you from Kimavi, Please visit us at Kimavi.Com for more portrait videos
- Category
- ELVIS
Commenting disabled.